ARMP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARMP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-23), Armata Pharmaceuticals's current share price is $2.60. Armata Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $66.94. Armata Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.04.
The historical rank and industry rank for Armata Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Armata Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 0.30. The lowest was 0.01. And the median was 0.08.
ARMP's Cyclically Adjusted PB Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Armata Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was $-1.564. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $66.94 for the trailing ten years ended in Mar. 2024.
The historical data trend for Armata Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Armata Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 0.23 | 0.16 | 0.42 | 0.09 | 0.06 |
For the Biotechnology subindustry, Armata Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Armata Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Armata Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 2.60 | / | 66.94 | |
= | 0.04 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Armata Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Armata Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:
Adj_Book | = | Book Value per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | -1.564 | / | 131.7762 | * | 131.7762 | |
= | -1.564 |
Current CPI (Mar. 2024) = 131.7762.
Armata Pharmaceuticals Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201406 | -349.233 | 100.560 | -457.645 |
201409 | 420.755 | 100.428 | 552.093 |
201412 | 120.808 | 99.070 | 160.691 |
201503 | -77.462 | 99.621 | -102.465 |
201506 | 321.099 | 100.684 | 420.258 |
201509 | 372.751 | 100.392 | 489.282 |
201512 | 302.570 | 99.792 | 399.545 |
201603 | 211.733 | 100.470 | 277.707 |
201606 | 270.477 | 101.688 | 350.507 |
201609 | 229.485 | 101.861 | 296.882 |
201612 | 82.559 | 101.863 | 106.804 |
201703 | 56.449 | 102.862 | 72.317 |
201706 | 16.148 | 103.349 | 20.590 |
201709 | 14.648 | 104.136 | 18.536 |
201712 | 11.394 | 104.011 | 14.436 |
201803 | 9.600 | 105.290 | 12.015 |
201806 | 7.089 | 106.317 | 8.787 |
201809 | 5.826 | 106.507 | 7.208 |
201812 | 3.674 | 105.998 | 4.568 |
201903 | 2.119 | 107.251 | 2.604 |
201906 | 2.272 | 108.070 | 2.770 |
201909 | 1.825 | 108.329 | 2.220 |
201912 | 1.471 | 108.420 | 1.788 |
202003 | 1.796 | 108.902 | 2.173 |
202006 | 1.590 | 108.767 | 1.926 |
202009 | 1.319 | 109.815 | 1.583 |
202012 | 1.009 | 109.897 | 1.210 |
202103 | 1.364 | 111.754 | 1.608 |
202106 | 1.148 | 114.631 | 1.320 |
202109 | 0.952 | 115.734 | 1.084 |
202112 | 0.937 | 117.630 | 1.050 |
202203 | 1.704 | 121.301 | 1.851 |
202206 | 1.475 | 125.017 | 1.555 |
202209 | 1.261 | 125.227 | 1.327 |
202212 | 0.998 | 125.222 | 1.050 |
202303 | 0.621 | 127.348 | 0.643 |
202306 | 0.530 | 128.729 | 0.543 |
202309 | -0.343 | 129.860 | -0.348 |
202312 | -0.888 | 129.419 | -0.904 |
202403 | -1.564 | 131.776 | -1.564 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Armata Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Rychlik | officer: Corporate Controller and PFO | 5005 MCCONNELL AVENUE, LOS ANGELES CA 90066 |
Deborah Birx | director, officer: Chief Executive Officer | 3300 LOWELL STREET NW, WASHINGTON DC 20008 |
Julianne Averill | officer: Chief Financial Officer | 361 NEWBURY STREET, SUITE 500, BOSTON MA 02115 |
Erin Butler | officer: Vice President,Finance & Admin | 4375 LOMA RIVIERA COURT, SAN DIEGO CA 92110 |
Theravance Inc | director, 10 percent owner | 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010 |
Jules Haimovitz | director | 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004 |
Innoviva Strategic Opportunities Llc | director, 10 percent owner | 1209 ORANGE STREET, WILMINGTON DE 19801 |
Robin Kramer | director | 999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109 |
Steven Robert Martin | officer: Chief Financial Officer | 11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
Kostas D Odysseas | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Sarah J. Schlesinger | director | C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Jeremy Curnock Cook | director | TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101 |
Michael S Perry | director | C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155 |
Todd C. Peterson | director | C/O ARMATA PHARMACEUTICALS, INC., 4503 GLENCOE AVENUE, MARINA DEL REY CA 90292 |
H Stewart Parker | director |
From GuruFocus
By PRNewswire PRNewswire • 06-01-2022
By PRNewswire • 09-21-2023
By PRNewswire PRNewswire • 03-31-2022
By PRNewswire PRNewswire • 05-11-2023
By GuruFocus Research • 11-15-2023
By PRNewswire • 07-11-2023
By PRNewswire PRNewswire • 11-09-2022
By PRNewswire PRNewswire • 07-11-2022
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 07-02-2022